Soligenix GAAP EPS of -$0.18, revenue of $0.1M
Seeking Alpha News (Fri, 10-May 7:45 AM ET)
Soligenix Announces Recent Accomplishments And First Quarter 2024 Financial Results
PRNewswire (Fri, 10-May 7:30 AM ET)
Soligenix to Present at Upcoming Conferences
PRNewswire (Mon, 6-May 7:30 AM ET)
PRNewswire (Thu, 25-Apr 7:30 AM ET)
Soligenix Announces Pricing of $4.75 Million Public Offering
PRNewswire (Thu, 18-Apr 8:30 AM ET)
PRNewswire (Mon, 15-Apr 7:30 AM ET)
PRNewswire (Thu, 11-Apr 7:30 AM ET)
PRNewswire (Wed, 3-Apr 7:30 AM ET)
Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results
PRNewswire (Fri, 15-Mar 7:30 AM ET)
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
Soligenix trades on the NASDAQ stock market under the symbol SNGX.
As of May 10, 2024, SNGX stock price declined to $0.40 with 130,909 million shares trading.
SNGX has a beta of 0.36, meaning it tends to be less sensitive to market movements. SNGX has a correlation of 0.00 to the broad based SPY ETF.
SNGX has a market cap of $5.68 million. This is considered a Sub-Micro Cap stock.
Last quarter Soligenix reported $205,453 in Revenue and -$.06 earnings per share. This beat revenue expectation by $5,453 and exceeded earnings estimates by $.13.
In the last 3 years, SNGX stock traded as high as $20.10 and as low as $.37.
The top ETF exchange traded funds that SNGX belongs to (by Net Assets): VXF.
SNGX has underperformed the market in the last year with a price return of -51.1% while the SPY ETF gained +27.8%. SNGX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -41.3% and -3.9%, respectively, while the SPY returned +4.2% and +2.5%, respectively.
SNGX support price is $.37 and resistance is $.44 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SNGX stock will trade within this expected range on the day.